India's MedTech Oppertunity: The TEPA Advantage for Swiss Companies
Structured market entry with tariff advantages and proven demand.
✽ The Market
A High-Growth Market with Unprecedented Access
India's MedTech sector is experiencing robust growth, driven by a confluence of demographic shifts, expanding healthcare infrastructure, and strong market preference for sophisticated foreign technology. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 21%, presenting a significant opportunity for Swiss exporters.
MARKET CAGR
21%
Projected growth through 2027
HOSPITAL EXSPANSION
100+
Projects by major chains
PE/VC INVESTMENT
$14.5B
In last 5 years
Why Now? The TEPA Adavntage
A Time-Sensitive Window of Opportunity
Tariff Elimination
Current 10% duty phased out over 5-10 years
8.5%
Margin of preference for Swiss exporters
Patent Protection
Enhanced IP rights and legal certainty
Non-discriminatory protection for imported products
Exceeds WTO TRIPS standards
Time Window
TEPA effective October 1, 2025
5-10
Years to capture advantage
Tariff Reduction Timeline
Source: Government of India | Ministry of Commerce and Industry
Four Pillars of Growth
Evolving Demographics
By 2030, 30% of India's population will be over 45 years old, driving demand for advanced medical equipment.
Healthcare Infrastructure
100+ expansion projects by major hospital chains creating significant procurement opportunities.
Rising Affluence
Growing middle class with higher disposable income and broader health insurance penetration.
Government Support
PLI scheme and Medical Device Parks offering infrastructure and R&D support.
The Swiss Advantage
Qualtiy, Innovation, and Trust in High-Value Segments
HS Code | Product Category | Leading Swiss Companies |
902110 | Orthopaedic | Zimmer Biomet, Smith & Nephew, Medacta, Spineart |
902129 | Dental Fittings | Straumann, Ivoclar Vivadent, Swissdent |
902131 | Artificial Joints | Zimmer Biomet, Smith & Nephew, Medacta |
902150 | Pacemakers | Medtronic, Biotronik |
901831 | Syringes | Ypsomed, BD Switzerland, Euro Swiss |
A Phased Approach to Market Success
Explore
Market validation, regulatory assessment, and partner identification to de-risk your entry.
Exploit
Market entry, distribution setup, and securing initial sales with proven partners.
Scale
Regional expansion, local manufacturing options, and R&D partnerships.
Navigating India's Regulatory Framework
With Confidence and Expert Support
Key Regulatory Requirements
Indian Authorized Agent: Mandatory local representative
Device Classification: Class A-D based on risk level
SUGAM Portal: Central online licensing system
CDSCO Registration: Central Drugs Standard Control Organization approval required
TEPA Advantage
The Trade and Economic Partnership Agreement provides a clear advantage by offering:
✓ Predictable tariff reduction schedule
✓ Enhanced IP protection
✓ Reduced regulatory risk
✓ Faster opposition proceedings
TEPA.swiss your Partner for Success
Indian MedTech Market
Market Research & Validation
In-depth analysis of market potential for your specific products, competitive landscape, and customer segments.
Regulatory Guidance
Expert support navigating CDSCO registration, SUGAM portal, and compliance requirements.
Partner Identification
Connection to qualified local distributors, manufactures, and healthcare partners
Strategic Consulting
Tailored advice on market entry strategy, pricing, channels, and long-term positioning
Join Us at Medical Fair Mumbai
As part of our "Explore" phase, we invite you to join the Swiss Pavilion at the upcoming Medical Fair in Mumbai. This is an unparalleled opportunity to showcase your products, network with key decision-makers in the Indian healthcare industry, and gain firsthand insights into the market.
Date
17-19 September 2026
Location
Bombay Exhibition Center (BEC)
Mumbai, India
Why Attend?
✓ Showcase your MedTech solutions
✓ Network with hospital chains and distributors
✓ Meet regulatory and compliance experts
✓ Gain market insights and competitive intelligence
✓ Connect with S-GE and TEPA.swiss partners
Begin Your India Market Entry Journey
Complete the form below to receive a complimentary consultation and learn more about how TEPA.swiss can support your growth.
Frequently Asked Questions
What is TEPA and when did it take effect?
The Trade and Economic Partnership Agreement (TEPA) between EFTA states (including Switzerland) and India took effect on October 1, 2025. It provides for gradual elimination of tariffs on medical devices over 5-10 years.
How long does the CDSCO registration process take?
The timeline varies by device class. Generally, expect 6-12 months for registration, depending on the complexity of your product and the completeness of your documentation. We help to expedite this process.
What is an Indian Authorized Agent (IAA)?
An IAA is a mandatory local representative who manages your registration with CDSCO, holds your import license, and serves as the primary regulatory contact in India. We can provide the IAA infrastructure and license.
When is Medical Fair Mumbai and how do I register?
17 -19 September 2026. Interested companies can indicate their interest in the sign-up form above, and we'll provide complete event details and registration information.
What is the cost structure for TEPA.swiss services?
We offer tiered packages based on your specific needs and market entry stage. Initial consultations are complimentary. Contact us to discuss a customized package for your company.
How do Swiss companies compare to other foreign competitors?
Swiss MedTech companies benefit from superior quality, strong brands, and advanced IP. TEPA adds tariff advantages and stronger IP protection, giving Swiss exporters a clear edge in India’s premium market.
Ready to Explore India's MedTech Opportunity?
Join the Swiss MedTech Cluster and gain access to market expertise, regulatory guidance, and a proven network of partners.